Stocks
By market cap · 34 stocks
- 1
PTCTPTC TherapeuticsRare-disease drugmaker spanning PKU, DMD, and gene therapy$5.45B+1.27% - 2
LEGNLegend Biotech (ADR)CARVYKTI commercializer and CAR-T developer$3.43B+0.22% - 3
PGENPrecigenPAPZIMEOS commercial-stage gene and cell therapy developer$2.75B+3.42% - 4
MESOMesoblast (ADR)Developer of allogeneic cell medicines$2.01B+2.62% - 5
IMCRImmunocore (ADR)ImmTAX therapy developer and KIMMTRAK marketer$1.64B+0.22% - 6
GLUEMonte Rosa TherapeuticsMolecular glue degrader drug developer$1.04B+0.82% - 7
SLBTSL SciencePreclinical immune-cell therapies and Taiwan exosome products$964.5M−0.58% - 8
SLDBSolid BiosciencesGene therapies for rare muscle and cardiac diseases$840.8M+4.03% - 9
DSGNDesign TherapeuticsGeneTAC developer for inherited genetic diseases$783.8M+5.54% - 10
MDXGMiMedxMaker of placental-tissue allografts for wound care$701.1M+1.98% - 11
PROKProKidneyAutologous cell therapy developer for advanced kidney disease$596.9M+4.24% - 12
PRMEPrime MedicinePrime Editing genetic therapy developer$576.2M+7.99% - 13
CAPRCapricor TherapeuticsDeramiocel-focused DMD cell-therapy developer$511.8M+5.06% - 14
KYTXKyverna TherapeuticsAutologous CAR-T developer for autoimmune diseases$432.9M+5.90% - 15
ARTVArtiva BiotherapeuticsDeveloper of off-the-shelf NK-cell therapies$382.8M+3.77% - 16
FATEFateOff-the-shelf iPSC CAR T/NK pipeline$294.9M+1.38% - 17
TRDAEntrada TherapeuticsDeveloper of exon-skipping therapies for Duchenne muscular dystrophy$257.8M+2.48% - 18
LCTXLineage Cell TherapeuticsDeveloper of allogeneic cell-replacement therapies$251.8M+2.97% - 19
NAGENiagen BioscienceNAD+ science and Niagen supplements$242.1M+1.42% - 20
RNACCartesian TherapeuticsmRNA cell therapy developer for autoimmune disease$233.3M+2.27% - 21
MXCTMaxCyteFlow electroporation cell-engineering platform$130.7M+0.41% - 22
ATRAAtara BiotherapeuticsPartner-led EBV-targeted T-cell therapy support$84.5M−1.17% - 23
CELUCelularityPlacenta-derived cellular-medicine platforms$35.9M−3.23% - 24
MRKRMarker TherapeuticsMulti-antigen T-cell therapies for cancer$20.0M+2.08% - 25
GNTAGenenta Science (ADR)Tumor-targeted gene therapy and Italian industrial investments$13.0M+1.08% - 26
MSLESatellos BioscienceOral muscle-repair therapy developer for Duchenne muscular dystrophy$11.8M−3.34% - 27
ENLVEnlivexAllocetra cell therapy and RAIN treasury$11.7M−11.60% - 28
PLURPluriCell-expansion platform for therapies and cultivated foods$11.5M−2.80% - 29
GDTCCytoMed TherapeuticsDeveloper of off-the-shelf cancer cell therapies$11.5M−6.20% - 30
KALAKALA BIOBiotech AI platform and retained biologics assets$10.8M+7.09% - 31
LGVNLongeveronDeveloper of laromestrocel cell therapy$7.5M+11.02% - 32
XBIOXenetic BiosciencesDeveloper of DNase cancer-treatment adjuncts$6.9M−17.73% - 33
BRTXBioRestorative TherapiesAutologous cell therapy developer for chronic disc disease$3.7M+3.51% - 34
CELZCreative Medical TechnologyDeveloper of regenerative cell therapies and CaverStem kits$2.6M−11.80%